Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy

Benedicte Sjo Tislevoll, MD, Oda Helen Eck Fagerholt, Nello Blaser, MS, PhD, Monica Hellesøy, MS, PhD, Stein-Erik Gullaksen, MS, PhD, Pilar Ayuda Duran, MS, PhD, Laure Isabelle Piechaczyk, MS, Dagim Tadele, MS, Jørn Skavland, MS, PhD, Sonia Gavasso, MS, PhD, Jorrit Enserink, MS, PhD, Yngvar Fløisand, MD PhD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2018-99-116943

Published: 2018

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD

Blood (2015) 126 (23): 477.

https://doi.org/10.1182/blood.V126.23.477.477

Published: 2015

Journal Articles

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Riikka Karjalalainen, Tea Pemovska, Muntasir Mamun Majumder, Bhagwan Yadav, Jing Tang, Mika Kontro, Bjørn Gjertsen, MD PhD, Alun Parsons, Minna Suvela, Kimmo Porkka, Tero Aittokallio, Olli Kallioniemi, Krister Wennerberg, Jonathan Knowles, Caroline Heckman

Blood (2015) 126 (23): 867.

https://doi.org/10.1182/blood.V126.23.867.867

Published: 2015

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

Journal Articles

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline

David A. Rizzieri, MD, Norbert Vey, MD, PhD, Xavier Thomas, MD, Françoise Huguet, Richard F Schlenk, MD, Jürgen Krauter, MD, Ph.D., Thomas Kindler, MD, Bjorn Gjertsen, MD, PhD, Igor W. Blau, Malin Johansen, Trygve Bergeland, Athos Gianella-Borradori, Tove Flem Jacobsen, Jianyu Rao, MD, Utz Krug

Blood (2012) 120 (21): 46.

https://doi.org/10.1182/blood.V120.21.46.46

Published: 2012

Journal Articles

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Blood (2011) 118 (21): 784.

https://doi.org/10.1182/blood.V118.21.784.784

Published: 2011

Journal Articles

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response

David A. Rizzieri, MD, Norbert Vey, MD, Richard F. Schlenk, MD, Xavier Thomas, MD, PhD, Françoise Huguet, MD, Bjorn Gjertsen, MD, PhD, Jürgen Krauter, Igor Wolfgang Blau, Malin Johansen, Athos Gianelli-Borradori, Tove Flem Jacobsen, Jianyu Rao, MD, Utz Krug, MD

Blood (2011) 118 (21): 1533.

https://doi.org/10.1182/blood.V118.21.1533.1533

Published: 2011

NARROW

A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only